Compare FPF & IVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FPF | IVA |
|---|---|---|
| Founded | 2013 | 2011 |
| Country | United States | France |
| Employees | N/A | 77 |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 883.8M |
| IPO Year | N/A | N/A |
| Metric | FPF | IVA |
|---|---|---|
| Price | $18.04 | $3.94 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $16.20 |
| AVG Volume (30 Days) | 92.8K | ★ 1.3M |
| Earning Date | 01-01-0001 | 03-30-2026 |
| Dividend Yield | ★ 8.08% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $751.20 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $17.21 | $2.94 |
| 52 Week High | $19.75 | $7.98 |
| Indicator | FPF | IVA |
|---|---|---|
| Relative Strength Index (RSI) | 51.07 | 47.55 |
| Support Level | $17.58 | $3.79 |
| Resistance Level | $18.26 | $4.67 |
| Average True Range (ATR) | 0.19 | 0.18 |
| MACD | 0.03 | 0.08 |
| Stochastic Oscillator | 58.33 | 90.32 |
First Trust Inter Dur Pref& Income Fund is a diversified, closed-end management investment company. Its primary investment objective is to seek a high level of current income. Further, it has a secondary objective of capital appreciation. The Fund invests in the traditional preferred securities, hybrid preferred securities, floating rate & fixed-to-floating rate preferred securities, debt securities, convertible securities, and contingent convertible securities issued by U.S. and non-U.S. companies. Its investment portfolio includes industries such as Banks, Insurance, Capital Markets, Electric Utilities, Oil, Gas & Consumable Fuels, Food Products, and others.
Inventiva SA is a France-based clinical-stage biopharmaceutical company focused on the development of oral small-molecule therapies for the treatment of MASH. The wholly-owned research and development facility and a team with expertise and experience in the development of compounds that target nuclear receptors, transcription factors and epigenetic modulation. Leveraging the expertise, the company is also advancing lanifibranor for the treatment of MASH and has a pipeline of earlier-stage therapeutic programs in oncology. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France.